TCGA-LD-A66U-01A-11R-A31O-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 22
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.360
- COAGULATION+0.340
- KRAS_SIGNALING_DN+0.330
- ALLOGRAFT_REJECTION+0.320
- ESTROGEN_RESPONSE_EARLY+0.320
- ESTROGEN_RESPONSE_LATE+0.320
- TNFA_SIGNALING_VIA_NFKB+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- P53_PATHWAY+0.170
- PANCREAS_BETA_CELLS+0.150
Top 10 suppressed
- G2M_CHECKPOINT-0.570
- PROTEIN_SECRETION-0.560
- E2F_TARGETS-0.520
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.420
- UV_RESPONSE_DN-0.340
- ANDROGEN_RESPONSE-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MYC_TARGETS_V1-0.300
- HEDGEHOG_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.912 |
| 2 | SRR5088872 | — | — | 0.902 |
| 3 | MNG1103 | — | — | 0.899 |
| 4 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.889 |
| 5 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.883 |
| 6 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.873 |
| 7 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.866 |
| 8 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.864 |
| 9 | TCGA-BH-A42U-01A-12R-A24H-07 | — | B | 0.864 |
| 10 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |